Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

Post Myocardial Infarction Clinical Trial

Official title:
A Multicenter Study to Evaluate the Long-term Safety and Tolerability of Open-label LCZ696 in Patients With Acute Myocardial Infarction Who Previously Participated in CLCZ696G2301 (PARADISE-MI)

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to collect long-term safety and tolerability data of LCZ696 and to provide open-label LCZ696 to eligible participants who completed CLCZ696G2301 study (PARADISE-MI) if LCZ696 is shown to have a positive benefit-risk profile in comparison to ramipril in reducing risk of cardiovascular (CV) mortality and development of heart failure in participants enrolled in the PARADISE-MI study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04637555
Study type	Interventional
Source	Novartis
Contact
Status	Withdrawn
Phase	Phase 3
Start date	May 26, 2021
Completion date	June 1, 2023

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01664611` - Daily REmote Ischaemic Conditioning Following Acute Myocardial Infarction	N/A
	Completed	`NCT00605631` - The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study	N/A